Pfa & azt

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Pfa & azt
• 英文别名: 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;phosphonoformic acid
• 化学式: C11H16N5O9P
• 分子量: 393.25
• InChiKey: JRDZNEWRNRFBRY-HNPMAXIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.35
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  188
• 氢给体数：
  5
• 氢受体数：
  11

文献信息

• Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
  申请人：Kung Hsiang-Fu

  公开号：US20050004063A1

  公开（公告）日：2005-01-06

  The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.

  本发明涉及用于治疗人类严重急性呼吸系统综合症（SARS）的治疗剂。特别是，本发明涉及用于抑制 hSARS 病毒感染和复制的 RNA 干扰（RNAi）分子。最好，RNAi 分子以 hSARS 病毒的复制酶区或 hSARS 病毒基因的不同位点组合为靶点。本发明还包括使用 RNAi 分子预防和/或治疗 SARS 的方法。本发明还包括含有治疗有效量的 RNAi 分子的疫苗和试剂盒。
• High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
  申请人：Peiris S.M. Joseph

  公开号：US20050181357A1

  公开（公告）日：2005-08-18

  The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.

  本发明涉及一种针对引起人类严重急性呼吸系统综合症（SARS）的病毒（"hSARS 病毒"）的高通量诊断检测方法。特别是，本发明涉及一种高通量反转录-PCR 诊断试验，用于检测与 SARS 相关的 冠状病毒 (SARS-CoV）的高通量反转录-PCR 诊断试验。本检测方法是一种快速、可靠的检测方法，可用于诊断和监测 SARS 的传播，它以 hSARS 病毒的 N（核帽）基因的核苷酸序列为基础。本方法消除了假阴性结果，提高了检测灵敏度。本发明还公开了 hSARS 病毒的 S（钉螺）基因。本发明还涉及 hSARS 病毒的 N 基因和 S 基因产物的氨基酸序列的推导，以及 N 基因和 S 基因产物在诊断方法中的应用。本发明还包括由针对 N 基因或 S 基因产物产生的抗体组成的诊断方法和试剂盒。
• COMPOSITIONS AND PROCESSES RELATING TO HUMAN BOCAVIRUS
  申请人：The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services,

  公开号：EP2268801A2

  公开（公告）日：2011-01-05
• EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF
  申请人：The Government Of The United States Of America As Reresented By The Secretary Of The Department Of Health & Human Services

  公开号：EP2297186A2

  公开（公告）日：2011-03-23
• INFEKTIÖSE BRONCHITIS (IB)-VIRUS VARIANTEN UND DIESBEZÜGLICHE ZUSAMMENSETZUNGEN, VERWENDUNGEN UND VERFAHREN
  申请人：Anicon Labor GmbH

  公开号：EP3497206A1

  公开（公告）日：2019-06-19